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Abstract
Background: S100A4 is a small Ca2+-binding protein of the S100 family with metastasis-promoting
properties. Recently, secreted S100A4 protein has been shown to possess a number of functions,
including induction of angiogenesis, stimulation of cell motility and neurite extension.
Methods: Cell cultures from two human osteosarcoma cell lines, OHS and its anti-S100A4
ribozyme transfected counterpart II-11b, was treated with IFN-γ and recombinant S100A4 in order
to study the sensitizing effects of extracellular S100A4 on IFN-γ mediated apoptosis. Induction of
apoptosis was demonstrated by DNA fragmentation, cleavage of poly (ADP-ribose) polymerase
and Lamin B.
Results: In the present work, we found that the S100A4-expressing human osteosarcoma cell line
OHS was more sensitive to IFN-γ-mediated apoptosis than the II-11b cells. S100A4 protein was
detected in conditioned medium from OHS cells, but not from II-11b cells, and addition of
recombinant S100A4 to the cell medium sensitized II-11b cells to apoptosis induced by IFN-γ. The
S100A4/IFN-γ-mediated induction of apoptosis was shown to be independent of caspase activation,
but dependent on the formation of reactive oxygen species. Furthermore, addition of extracellular
S100A4 was demonstrated to activate nuclear factor-κB (NF-κB).
Conclusion: In conclusion, we have shown that S100A4 sensitizes osteosarcoma cells to IFN-γ-
mediated induction of apoptosis. Additionally, extracellular S100A4 activates NF-κB, but whether
these events are causally related remains unknown.
Background
The S100 protein family consists of at least 21 small,
acidic, Ca2+-binding proteins with different expression
patterns and apparently diverse functional and biological
properties [1]. The S100A4 protein has been associated
with increased metastatic capacity of cancer cells [2-4], but
how S100A4 exerts the metastasis-promoting effects is
still incompletely understood. S100A4 has been shown to
interact with a number of cytoskeleton-associated pro-
teins, including non-muscle myosin [5], actin [6] and
non-muscle tropomyosin [7], thereby possibly affecting
cell motility. In addition, we have previously demon-
strated an association between S100A4, matrix metallo-
proteinases and the invasive capacity of osteosarcoma
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secreted, and suggested extracellular functions include
induction of angiogenesis [9], stimulation of cell motility
[10], and stimulation of neurite outgrowth [11]. Moreo-
ver, we have recently demonstrated nuclear localization of
S100A4, and an association between nuclear expression
and tumor stage in colorectal cancer [12], indicating
other, yet undiscovered, functions of S100A4. Finally,
S100A4 has been reported to interact with the tumor sup-
pressor protein p53 and to modulate transcription of
downstream target genes, thus influencing p53-mediated
apoptosis [13].
Interferon-gamma (IFN-γ) is a pleiotropic cytokine
secreted from activated T lymphocytes and natural killer
cells. It can activate and suppress a number of target genes,
leading to various effects, including inhibition of viral
replication, activation of immune cells and induction of
cell cycle arrest and apoptosis [14,15]. Apoptosis is a proc-
ess of programmed cell death characterized by chromatin
condensation and DNA fragmentation, plasma mem-
brane blebbing and cell shrinkage. One of the central exe-
cutioners of the apoptotic pathway are the caspases [16].
It has, however, become evident that a number of caspase-
independent pathways exist, leading to programmed cell
death involving cathepsins [17], apoptosis inducing factor
[18], calpains, AP24 and other serine proteases [19]. Evi-
dence has been provided showing that IFN-γ is able to
induce programmed cell death by both caspase-depend-
ent and -independent pathways, e.g. through cathepsin D
[20], caspase-1 [21], TNF-related apoptosis-inducing lig-
and (TRAIL) [22] and Fas/FasL [23].
Searching for cytokines and signal transduction modula-
tors affecting S100A4 expression, we recently discovered
that IFN-γ downregulated S100A4 transcription and
induced apoptosis in the human osteosarcoma cell line
OHS [24]. In the corresponding anti-S100A4 ribozyme-
transfected cell line II-11b [3], apoptosis induction was
remarkably lower, and these findings prompted us to
investigate whether S100A4 could affect IFN-γ-mediated
apoptosis. In the present study, we show that S100A4 can
be secreted from these human osteosarcoma cells, and
that extracellular addition of rS100A4 sensitizes cells to
apoptosis induced by IFN-γ. Furthermore, we demon-
strate that this cell death pathway is independent of cas-
pases, but possibly dependent upon NF-κB
transactivation and generation of reactive oxygen species
(ROS).
Methods
Cell culture and treatment
The human osteosarcoma cell line OHS and its anti-
S100A4 ribozyme transfected counterpart II-11b have
been described previously [8]. Cell lines were cultivated in
RPMI-1640 (Bio Whittaker, Verviers, Belgium) containing
10% fetal bovine serum (FBS; Biochrome KG, Berlin, Ger-
many), 1 mM Hepes, and 2 mM Glutamax (GIBCO BRL,
Life Technologies, Paisley, UK). For all experiments, sub-
confluent cultures were trypsinated and seeded at 1.5 ×
104 cells/cm2. After overnight incubation, the culture
medium was replaced with medium in presence or
absence of IFN-γ and recombinant S100 proteins, and har-
vested as indicated in the text. Where indicated, protease
inhibitors or antioxidants were added to the cell culture
simultaneously as IFN-γ.
Materials
Human recombinant IFN-γ, L-NMMA, zVAD-fmk,
zYVAD-fmk, zVDVAD-fmk, zDEVD-fmk, zVEID-fmk,
zIETD-fmk, zLEHD-fmk, zFA-fmk and E64 were pur-
chased from Calbiochem (San Diego, CA, USA). N-acetyl-
cysteine was from Sigma Chemical Co (St Louis, MO,
USA).
Production of proteins
Histidine-tagged mouse recombinant S100A4 was cloned
into the pQE30 vector (kindly provided by E. Lukanidin,
Institute of Cancer Biology, Copenhagen, Denmark),
expressed in E. coli, purified on a Ni2+-column and dia-
lyzed against phosphate-buffered saline. A satisfactory
degree of purity was confirmed by SDS polyacrylamide gel
electrophoresis (SDS-PAGE) where a single band was vis-
ualized by silver staining. Verification of the identity of
the protein was performed using matrix-assisted laser des-
orption ionization-time-of-flight mass spectrometry
(MALDI). Human recombinant S100A10 and S100A13
tagged with maltose-binding protein were kindly pro-
vided by C. S. Skjerpen (Dep. of Biochemistry, The Norwe-
gian Radium Hospital, Oslo, Norway).
Cell viability
Cell viability was estimated by measuring metabolic activ-
ity using CellTiter 96® AQueous One Solution Reagent
(MTS) (Promega, Madison, WI, USA) according to the
manufacturer's manual. The absorbance at 490 nm was
recorded using a Wallac 1420 Victor2 Multilabel counter
(Wallac Oy, Turku, Finland).
Western blot analysis
Protein lysates were prepared in 50 mM Tris-HCl (pH 7.5)
containing 150 mM NaCl and 0.1% NP-40 with 1 mM
PMSF and 2 µg/ml each of pepstatin, aprotinin (Sigma
Chemical Co, St Louis, MO, USA) and leupeptin (Roche
Diagnostics, Mannheim, Germany). Total protein lysate
from each sample was separated on 8–12% SDS-polyacr-
ylamide gel electrophoresis, and transferred onto Immo-
bilon-P membranes (Millipore, Bedford, MA, USA)
according to the manufacturer's manual. As a loading and
transfer control, the membranes were stained with 0.1%Page 2 of 16
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with 10% non-fat dry milk in Tris-buffered saline with
0.25% Tween (TBST), blots were incubated for 1 h at
room temperature with rabbit polyclonal anti-poly (ADP-
ribose) polymerase (PARP; diluted 1:1000, Roche Diag-
nostics, Mannheim, Germany), mouse monoclonal anti-
lamin B (0.3 µg/ml; Oncogene Research Products, Boston,
MA, USA), mouse monoclonal anti-α-tubulin (0.3 µg/ml;
Oncogene Research Products, Boston, MA, USA), rabbit
polyclonal anti-caspase-1 (1:100; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), goat polyclonal anti-caspase-3
(1:2000; R&D Systems, Minneapolis, MN, USA), mouse
monoclonal anti-caspase-8 (1:5000; Alexis Biochemicals,
Montreal, Canada), mouse monoclonal anti-caspase-9
(1:1000; R&D Systems, Minneapolis, MN, USA), rabbit
polyclonal anti-caspase-12 (1:2000; Oncogene Research
Products, San Diego, CA, USA), mouse monoclonal anti-
NFκB p65 (1:1000, Cell Signaling Technology Inc. Bev-
erly, MA, USA) or mouse monoclonal anti-phospho-IκBα
(Ser32/36) (1:2000, Cell Signaling Technology Inc. Bev-
erly, MA, USA). After washing, the blots were incubated
for 1 h at room temperature with a horseradish peroxi-
dase-conjugated secondary antibody (DAKO, Glostrup,
Denmark) diluted 1:5000. Anti-lamin B, anti-α-tubulin,
anti-PARP, anti-caspase-1, anti-caspase-8, anti-NFκB p65
and anti-phospho-IκBα were diluted in TBST with 5%
non-fat dry milk, anti-caspase-3 and anti-caspase-12 were
diluted in TBS containing 0.05% Tween and 2% non-fat
dry milk and anti-caspase-9 was diluted in TBS with
0.05% Tween, 1% non-fat dry milk and 1% BSA. Signals
were visualized using the ECL chemiluminescence sub-
strate (Amersham Pharmacia Biotech, Buckinghamshire,
UK).
DNA fragmentation analysis
Cells were resuspended in lysis buffer (10 mM Tris-HCl
pH 7.4, 10 mM NaCl, 10 mM EDTA, 0.5 % SDS and 0.5
µg/ml proteinase K) and incubated for 1 hour at 50°C.
High molecular weight DNA was precipitated by adding 1
M NaCl and subsequently incubated overnight at 4°C.
Samples were centrifuged for 30 min, 2700 g at 4°C, and
supernatants collected. 95 % ethanol was added, and
DNA precipitated overnight at -20°C. Samples were cen-
trifuged for 10 min, 10 000 rpm at 4°C, and pellets were
washed in 70 % ethanol and re-centrifuged. Thereafter,
pellets were air-dried and dissolved in 10 mM Tris-HCl
(pH 7.0), 15 mM NaCl, 1 mM EDTA and 0.2 mg/ml
RNAse A, and incubated for 1 h at room temperature.
DNA was separated by electrophoresis in 1.0 % agarose
gel containing ethidium bromide and photographed
under ultraviolet illumination.
Detection of S100A4 in cell culture medium
Cell culture medium from OHS and II-11b cells were har-
vested at 24, 48 and 72 hours, and immediately filtered
using a 0.45 µm filter to discard cells in suspension. From
each sample, 1.5 ml of medium was subjected to immu-
noprecipitation using 15 µg of rabbit polyclonal anti-
S100A4 (DAKO, Glostrup, Denmark) or 15 µg rabbit pol-
yclonal anti-p300 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Primary antibody binding was carried out in
cell culture medium at 4°C overnight. Thereafter, anti-
body was precipitated using Protein A Sepharose beads for
1 h at 4°C and eluted in loading buffer. Samples were sub-
jected to Western blot analysis as described above using
rabbit polyclonal anti-S100A4 diluted 1:300 in TBST.
Transient transfection and plasmid constructs
The NF-κB reporter construct containing three NF-κB
response elements (i.e., sites identical to the κB site from
the Igκ light chain promoter) driving luciferase expression
has been described previously [25]. 1.0 × 106 II-11b cells
were transiently transfected with 10 µg of the NF-κB
reporter construct using electroporation (240 V). Thereaf-
ter, cells were seeded in 96-well plates at a density of 4.5 ×
104 cells/cm2 and incubated in the absence or presence of
rS100A4 and zFA-fmk. Cells were harvested 48 h later and
assayed for luciferase activity using the Luciferase Assay
System (Promega, Madison, WI, USA) according to the
manufacturer's manual.
Statistical analysis
All statistical analyses were performed using Student's t-
test. P-values less than 0.05 were considered to be statisti-
cally significant.
Results
OHS cells are more sensitive than II-11b cells to IFN-γ-
mediated suppression of cell viability
We have previously observed that the human osteosar-
coma cell line OHS is more sensitive to IFN-γ induced
apoptosis than the S100A4-ribozyme transfected counter-
part II-11b [24]. To examine the effects of IFN-γ on cell
viability in more detail, time- and dose-response experi-
ments were performed (Fig. 1A and 1B). In OHS cells,
addition of 1 u/ml IFN-γ had no effect on cell viability,
while an increasing amount of cell death was observed
with higher concentrations. On the other hand, II-11b
cells only showed a marked reduction in cell number after
treatment with 1000 u/ml IFN-γ for 72 hours.
IFN-γ induces apoptosis in OHS Cells
Previously, we have shown that treatment of OHS cells
with IFN-γ induced a significant increase in the fraction of
apoptotic cells, while the cell cycle distribution remained
unchanged [24]. Thus, it seemed plausible that the
reduced cell viability could be due to induction of apop-
tosis, and to confirm this hypothesis, we investigated
some of the known hallmarks of the apoptotic process. As
seen in Fig. 2A, IFN-γ induced DNA fragmentation in OHSPage 3 of 16
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BMC Cancer 2004, 4:52 http://www.biomedcentral.com/1471-2407/4/52OHS cells are more sensitive than II-11b cells to IFN-γ-mediated suppression of cell viabilityFigure 1
OHS cells are more sensitive than II-11b cells to IFN-γ-mediated suppression of cell viability. Cell viability was 
measured in OHS cells (A) and II-11b cells (B) after treatment with the indicated concentrations of IFN-γ for 24, 48 and 72 
hours. In each experiment, untreated control cells were included at all time points, and all values are given as a percentage of 
corresponding untreated control cells. The results are presented as mean values ± S.D. of at least three independent experi-
ments performed in triplicate. *, p < 0.0001 and **, p < 0.05 as compared to untreated control cells.
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of poly (ADP-ribose) polymerase (PARP) and lamin B
(Fig. 2B). Taken together, these results clearly demon-
strated that IFN-γ-treatment induces apoptosis in OHS
cells.
Detection of S100A4 in cell culture medium
When performing the OHS cell culture experiments, we
observed that, when keeping the concentration of IFN-γ
constant, decreasing the volume of cell culture medium or
increasing the number of cells resulted in increased cell
death (data not shown). This observation suggested that
the cells might secrete a soluble factor with impact on the
level of apoptosis induced by IFN-γ. Since the II-11b cells
are derived from the OHS cells by transfection with an
S100A4-specific ribozyme, this finding prompted us to
investigate whether S100A4 is secreted from these cells,
and whether extracellular S100A4 could cooperate with
IFN-γ in induction of apoptosis. Fig. 3 shows an immuno-
precipitation of cell culture medium from OHS and II-11b
cells grown for 24, 48 and 72 hours. This clearly demon-
strated that S100A4 is present in cell culture medium from
OHS cells, and to a much lesser extent from II-11b cells. A
small amount of S100A4 was also detected in the cell cul-
ture medium control. This possibly reflects bovine
S100A4 present in fetal calf serum added to the medium,
but the exact nature of this signal has not been further
investigated. To exclude cell lysis as the cause of extracel-
lular S100A4, lactate dehydrogenase activity was meas-
ured in the conditioned culture medium. No significant
increase in enzyme activity was detected, supporting the
hypothesis that S100A4 is actively secreted (data not
shown). Importantly, cell culture medium from OHS cells
cultured for 72 hours immunoprecipitated with a rabbit
DNA fragmentation, PARP and Lamin B cleavage in IFN-γ-treated OHS cellsFigure 2
DNA fragmentation, PARP and Lamin B cleavage in IFN-γ-treated OHS cells. A, Ethidium bromide stained agarose 
gel of DNA isolated from OHS cells grown with or without 100 u/ml IFN-γ for 72 hours. B, Western blot analysis of the 
expression of PARP and Lamin B in total cell lysates. OHS cells were left untreated (-) or treated with 100 u/ml IFN-γ (+) for 
24, 48 and 72 hours, and lysates subjected to Western blot analysis as described in the "Materials and Methods" section.
75
100
150
75
50
24 h 48 h 72 h
++ +- - -
kDa
PARP
lamin B
A B
c
o
n
tr
o
l
IF
N
-γPage 5 of 16
(page number not for citation purposes)
BMC Cancer 2004, 4:52 http://www.biomedcentral.com/1471-2407/4/52polyclonal anti-p300 antibody did not give any S100A4-
signal, indicating that the detection of S100A4 was not
due to unspecific binding.
Sensitization of IFN-γ-mediated apoptosis by extracellular 
S100A4
In order to investigate whether extracellular S100A4 could
increase apoptosis induced by IFN-γ, recombinant
S100A4 (rS100A4) was added to the cell culture medium
of OHS and II-11b cells in addition to IFN-γ. Addition of
rS100A4 alone had no effect on cell viability at concentra-
tions ranging from 400 pg/ml to 20 µg/ml (Fig. 4 and data
not shown). On the other hand, when 20 µg/ml of
rS100A4 was added together with 100 u/ml IFN-γ to II-
11b cells, a significant decrease in cell viability was
observed (Fig. 4B). In fact, when II-11b cells were incu-
bated with 20 µg/ml rS100A4, the level of apoptosis
induced by IFN-γ was similar as in OHS cells. Addition of
rS100A4 to OHS cells also increased the IFN-γ-mediated
cell death, thus seemingly adding to the effects of the
endogenously produced extracellular S100A4 (Fig 4A).
Accordingly, a significant decrease in cell viability was
seen at lower concentrations of added rS100A4 in OHS
cells than in II-11b cells. Furthermore, we made attempts
to neutralize the secreted S100A4 protein by adding anti-
S100A4 antibodies to the cell culture medium of IFN-γ
treated OHS cells, but were unable to detect any decrease
in the amount of cell death (data not shown). Possibly,
the antibodies used (DAKO, Glostup, Denmark, as well as
three in-house produced monoclonal antibodies [26])
were not able to block the activity of extracellular S100A4.
S100 proteins share a high degree of sequence homology;
therefore it was of interest to investigate whether other
S100 proteins were able to sensitize tumor cells to IFN-γ-
mediated cell death. Addition of 20 µg/ml recombinant
S100A10 or S100A13 had no effect on apoptosis induc-
tion by IFN-γ in II-11b cells. Thus, it seems unlikely that
the observed effects are a general feature of S100 proteins,
but whether other S100 proteins than those tested here
could possess IFN-γ-sensitizing properties requires further
investigation. The possibility exists that rS100A4 and IFN-
γ induce a different type of cell death in II-11b cells than
the IFN-γ-mediated apoptosis in OHS cells. DNA frag-
mentation (Fig. 5A) as well as PARP and Lamin B cleavage
(Fig. 5A) were demonstrated also in II-11b cells, suggest-
ing that addition of recombinant S100A4 actually mimics
the biological effects of endogenous S100A4 in these
experiments.
IFN-γ-mediated apoptosis in OHS dells is caspase-
independent
Caspase-mediated apoptosis is the most important pro-
gram of cell death. In order to investigate whether IFN-γ
activated the caspase cascade in our cell system, we have
followed two different approaches: detection of activated
caspases by Western blotting and treatment of cell cultures
with caspase inhibitors. Using specific antibodies detect-
ing both the proenzyme and the active form of caspase-1,
-3, -8, -9 and -12, we were not able to detect any activation
of caspase-1, -3, -8 or -12 (Fig. 6 and data not shown).
However, the caspase-9 antibody detected a weak, but dis-
tinct, ~37 kDa band in IFN-γ treated cells at 48 and 72 h
and also in control cells at 72 h. This probably corre-
sponds to one of the active forms of caspase-9.
OHS cells secrete S100A4Figure 3
OHS cells secrete S100A4. Immunoprecipitation of cell culture medium alone (control) or cell culture medium from II-11b 
and OHS cells cultured for 24, 48 and 72 hours as indicated. 1.5 ml of medium was immunoprecipitated using rabbit polyclonal 
anti-S100A4 or anti-p300, and subsequently immunoblotted with anti-S100A4.
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BMC Cancer 2004, 4:52 http://www.biomedcentral.com/1471-2407/4/52Addition of recombinant S100A4 sensitizes OHS and II-11b cells to IFN-γ-induced apoptosisFigure 4
Addition of recombinant S100A4 sensitizes OHS and II-11b cells to IFN-γ-induced apoptosis. Cell viability was 
measured in OHS and II-11b cells after addition of the indicated concentrations of recombinant S100A4 to the cell culture 
medium with or without 100 u/ml IFN-γ. All values are given as a percentage of viable cells relative to untreated control cells. 
The results are presented as mean values ± S.D. of at least three independent experiments performed in triplicate. *, p < 
0.0001 and **, p < 0.05 as compared to untreated control cells.
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the proenzyme of caspase-3 in IFN-γ treated cells at 48 and
72 h (Fig. 6). This could possibly indicate a suppression of
caspase-3 expression by IFN-γ or activation of caspase-3
with resulting cleavage of the proenzyme. On the other
hand, no active forms of caspase-3 were detected, even
when exposing the film for several hours. To ensure that
the antibodies were able to detect the mature forms,
immunotoxin-treated breast cancer cells were included as
a positive control [27]. Furthermore, the pan-caspase
inhibitor zVAD-fmk inhibited IFN-γ-induced cell death,
albeit only at high concentrations (Fig. 7). zVAD-fmk sup-
pressed IFN-γ-mediated apoptosis significantly at 125 µM,
whereas 50 µM inhibited cell death non-significantly, and
10 µM zVAD-fmk had no effect on apoptosis inhibition.
The latter concentration has been reported to be sufficient
to inhibit most caspases [28], therefore it seems likely that
the observed effect of zVAD-fmk could be due to inhibi-
tion of other proteases or signaling events than caspases.
In addition, inhibition of caspase-1 (zYVAD-fmk), cas-
pase-2 (zVDVAD-fmk), caspase-3 and -7 (zDEVD-fmk),
caspase-6 (zVEID-fmk), caspase-8 (zIETD-fmk) and cas-
pase-9 (zLEHD-fmk) had no effect on IFN-γ-induced cell
death at concentrations up to 50 µM. Taken together, we
have not observed any activation of caspases-1, -3, -8 or -
12, whereas a low-level activation of caspase-9 was
detected. Inhibitors against a range of caspases including
caspase-9 did not suppress induction of cell death; hence,
from these experiments we concluded that the cell death
program induced by IFN-γ in OHS cells most likely is
caspase-independent.
Reactive oxygen species mediate IFN-γ-induced apoptosis
The caspase inhibitors used in the experiments above were
solved in dimethyl sulfoxide (DMSO), and therefore
DMSO was included as a negative control. Surprisingly, a
significant inhibition of IFN-γ-induced apoptosis was
observed using 0.25 % DMSO (Fig. 7). One of the known
biological properties of DMSO is scavenging of hydroxyl
radicals, indicating that the generation of reactive oxygen
species (ROS) could be implicated in the observed
induction of apoptosis. Furthermore, treatment with the
DNA fragmentation, PARP and Lamin B cleavage in rS100A4/IFN-γ-treated II-11b cellsFigure 5
DNA fragmentation, PARP and Lamin B cleavage in rS100A4/IFN-γ-treated II-11b cells. A, Ethidium bromide 
stained agarose gel of DNA isolated from II-11b cells. Cells were stimulated or left untreated with 100 u/ml IFN-γ for 72 hours 
in the presence or absence of 20 µg/ml rS100A4 as indicated. B, Western blot analysis of the expression of PARP and Lamin B 
in total cell lysates. II-11b cells were left untreated or treated with 100 u/ml IFN-γ and/or 20 µg/ml rS100A4 for 24, 48 and 72 
hours as indicated, and lysates subjected to Western blot analysis as described in "Materials and Methods".
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BMC Cancer 2004, 4:52 http://www.biomedcentral.com/1471-2407/4/52commonly used antioxidant N-acetylcysteine significantly
suppressed the IFN-γ-induced cell death (Fig. 7), whereas
the nitric oxide synthase inhibitor L-NMMA had no effect
(data not shown). Notably, zVAD-fmk was recently
shown to possess potent antioxidant effects at high con-
centrations [29] possibly explaining its inhibitory effects
shown above.
IFN-γ-mediated apoptosis in OHS cells is independent of 
cathepsin B, but possibly mediated by NF-κB
The pan-caspase inhibitor zVAD-fmk has previously been
shown to bind the cysteine protease cathepsin B and to
suppress cathepsin B activity in vitro [30]. Since cathepsins
are able to act as mediators of programmed cell death
[17], zVAD-fmk could possibly inhibit IFN-γ-induced
apoptosis through inhibition of cathepsin B. However,
50–250 µM E64 (a cysteine protease inhibitor) or 1–10
µM zFA-fmk (a cathepsin B inhibitor) failed to suppress
induction of the observed cell death (data not shown),
arguing against cathepsin B as a mediator of IFN-γ-
induced apoptosis. On the other hand, high
concentrations (125 µM) of zFA-fmk completely
inhibited induction of apoptosis (Fig. 7). Cathepsin B
activity is most likely suppressed at concentrations below
Western blot analysis of caspase-3 and caspase-9 in total cell lysatesFigure 6
Western blot analysis of caspase-3 and caspase-9 in total cell lysates. OHS cells were left untreated (-) or treated 
with 100 u/ml IFN-γ (+) for 24, 48 and 72 hours, and lysates subjected to Western blot analysis as described in "Materials and 
Methods". As a positive control for caspase activation, an immunotoxin-treated breast cancer cell line was included. α-tubulin 
serves as a loading control. The results shown are representative of three independent experiments.
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BMC Cancer 2004, 4:52 http://www.biomedcentral.com/1471-2407/4/5210 µM [28]; thus, we believe that the observed inhibition
by zFA-fmk is due to non-specific effects. Indeed, zFA-fmk
was recently shown to suppress transactivation by NF-κB
at concentrations similar to those used in these experi-
ments [30]. Interestingly, addition of rS100A4 to II-11b
cells lead to a marked induction of NF-κB activity in tran-
sient transfection assays using an NF-κB reporter con-
struct, and this induction was blocked by zFA-fmk (Fig.
8A). Furthermore, IκBα was phosphorylated upon addi-
tion of extracellular S100A4 (Fig. 8B), confirming activa-
tion of the NF-κB pathway. Taken together, these results
demonstrate that extracellular S100A4 activates NF-κB,
and suggest that the apoptosis induced by S100A4 and
IFN-γ could be mediated through an NF-κB-dependent
pathway, but whether these two events are actually caus-
ally connected remains to be investigated.
Discussion
IFN-γ induces apoptosis in a variety of different cell types,
but some cells are less susceptible or even resistant to IFN-
γ-mediated apoptosis. The reasons for this variation have
not been clearly elucidated, and given the biological
importance of IFN-γ, a better understanding of the mech-
anisms of IFN-γ-induced cell death is warranted. In the
present study, we have demonstrated that the Ca2+-bind-
ing protein S100A4 sensitizes human osteosarcoma cells
Inhibition of cell death by zVAD-fmk, zFA-fmk, DMSO and NACFigure 7
Inhibition of cell death by zVAD-fmk, zFA-fmk, DMSO and NAC. OHS cells were cultivated in the presence or 
absence of 100 u/ml IFN-γ and the indicated inhibitors for 72 hours, and cell viability was measured as described in "Materials 
and Methods". All values are given as a percentage of viable cells relative to corresponding cells treated with the indicated 
inhibitor, but without IFN-γ-treatment. Data are mean values ± S.D. The results represent at least three independent experi-
ments performed in triplicate. *, p < 0.001 and **, p < 0.05 as compared to IFN-γ-treated cells without inhibitor.
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BMC Cancer 2004, 4:52 http://www.biomedcentral.com/1471-2407/4/52to IFN-γ-induced apoptosis. Furthermore, we have shown
that the IFN-γ-mediated cell death is independent of
caspases, but possibly mediated by reactive oxygen spe-
cies. Finally, we have demonstrated that extracellular
S100A4 can activate NF-κB through increased phosphor-
ylation of IκBα, but whether this NF-κB transactivation is
required for apoptosis induction remains unknown.
Several of the S100 proteins are released into the extracel-
lular space, mostly by unknown mechanisms [1]. S100A4
secretion by human osteosarcoma cells is in agreement
with previous reports showing that S100A4 can be
released from non-malignant as well as tumor cells
[9,31,32]. The apoptosis-inducing properties of extracel-
lular S100A4 are, however, novel findings, emphasizing
the multiple functions of this protein. Other extracellular
S100 proteins also exert multiple effects, including proin-
flammatory activity, chemotaxis, neurite extension, stim-
ulation of angiogenesis, and regulation of cell survival [1].
Proapoptotic activity has, to our knowledge, only been
demonstrated previously for S100A1, S100B [33] and
S100A8/S100A9 [34]. S100B induces apoptosis by inter-
action with the multi-ligand cell surface receptor RAGE (a
member of the immunoglobulin superfamily) [33]. RAGE
also binds S100A12 [35], whereas no cell surface receptor
for S100A4 has been identified so far. In view of the sig-
nificant homology between S100 proteins, S100A4 could
possibly bind to and activate RAGE. However, treatment
with anti-RAGE IgG [35] up to 50 µg/ml had no inhibitory
effect on apoptosis induction (data not shown), and
higher concentrations were toxic to the cells. Hence,
another cell surface receptor might mediate S100A4-
induced sensitization of apoptosis, and in line with this,
RAGE-independent actions were recently demonstrated
for S100B [36]. Notably, mechanisms distinct from lig-
and-receptor interactions can also propagate proapoptotic
signals. S100A8/S100A9 induced apoptosis even when a
dialysis membrane hindered contact with the cells, possi-
bly by binding Zn2+ or other divalent cations [34].
Addition of 20 µg/ml rS100A4 (1.5 µM) to the cell
medium of II-11b cells was required to induce apoptosis
Recombinant S100A4 induces NF-κB transactivationFigure 8
Recombinant S100A4 induces NF-κB transactivation. A, II-11b cells were transiently transfected with an NF-κB 
reporter construct and incubated with or without 4 µg/ml rS100A4 and 50 µM zFA-fmk for 48 hours. Luciferase activity was 
expressed as fold induction of activity compared to the corresponding untreated control. Data are mean values ± S.D. The 
results represent at least three independent experiments performed in duplicate. *, p < 0.001 and **, p < 0.01 as compared to 
untreated control. ***, p < 0.005 as compared to rS100A4-treatment without zFA-fmk. B, Western blot analysis of NF-κB p65 
and phospho-IκBα (Ser32/36) in total cell lysates from II-11b cells, untreated or treated with 100 u/ml IFN-γ and/or 20 µg/ml 
rS100A4 for 24 and 48 hours as indicated.
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BMC Cancer 2004, 4:52 http://www.biomedcentral.com/1471-2407/4/52upon IFN-γ-treatment. Comparably, micromolar
amounts of S100B and S100A8/A9 were needed to induce
cell death [33,34]. Also S100A4-mediated neurite exten-
sion [11] as well as stimulation of angiogenesis [9] were
shown to require micromolar concentrations of recom-
binant protein. Whether native extracellular S100A4 is
present at these concentrations in our experiments is
unknown, as secreted S100A4 was not quantitatively
estimated.
In many cases, stimulation of tumor cells with a single
proapoptotic signal is not sufficient for induction of pro-
grammed cell death. On the other hand, a number of
cytokines and other proapoptotic signal substances can
increase the cells' sensitivity to other apoptosis-inducing
agents, thus initiating the cell death program. IFN-γ
induces apoptosis in synergism with a wide variety of such
agents, and particularly members of the tumor necrosis
factor (TNF) superfamily have been studied, e.g., TNF-α
[37], FasL [38], LIGHT [39] and TRAIL [22]. Our work
adds a novel proapoptotic signaling molecule to the list of
agents acting in synergism with IFN-γ to induce pro-
grammed cell death. The mechanisms by which S100A4
sensitizes the tumor cells to apoptosis induction are not
completely elucidated. Recently, Grigorian et al demon-
strated that S100A4 interacts with the tumor suppressor
protein p53 to enhance p53-dependent apoptosis. The
proposed mechanism was based on modulation of p53-
dependent transactivation of target genes [13]. The oste-
osarcoma cells used in our experiments harbor, however,
a mutated p53 protein [40], thus, S100A4 seemingly
enhance apoptosis through at least two distinct mecha-
nisms. One possible explanation for the apoptosis sensi-
tizing effects of S100A4 is that the protein positively
modulates IFN-γ-signaling in general. By studying the reg-
ulation of S100A4 expression, we have demonstrated that
extracellular S100A4 enhances IFN-γ-mediated suppres-
sion of S100A4 transcription (Pedersen et al., in prepara-
tion). These findings, in addition to the present work,
suggest that secreted S100A4 could sensitize IFN-γ-signal-
ing, and this possibility is currently under investigation.
Previously identified sensitizers of IFN-γ-signaling include
type I interferons (IFN-α/-β) [41] and IFN-γ itself [42]. Hu
et al. discusses, based on their experiments using periph-
eral blood mononuclear cells, that other factors probably
also exist to sensitize IFN-γ-signaling. Interestingly,
S100A4 is strongly expressed by T lymphocytes , but
whether lymphocytes also secrete S100A4 remains to be
investigated.
Our results suggest that S100A4-mediated NF-κB activa-
tion might be required for triggering the apoptotic process
induced by IFN-γ. To support this hypothesis, we made
attempts to inhibit NF-κB signaling by treatment with
SN50, a peptide that contains the p50 NLS and selectively
blocks nuclear translocation of NF-κB, but this lead to an
increased fraction of apoptotic cells. Schotte et al. suggest
that zFA-fmk has a promoter-specific NF-κB inhibitory
effect [30], whereas SN50 potently blocks all NF-κB activ-
ity, possibly explaining the divergent results. In general,
activation of NF-κB is regarded as an anti-apoptotic event
and as such, a total suppression of NF-κB activity could be
deleterious to cells. However, NF-κB apparently has a dual
role in apoptosis regulation, and cell death induction by
NF-κB has been reported in a variety of cell systems [43].
IFN-γ-induced apoptosis in OHS cells was shown to be
caspase-independent by two different approaches: (i) no
active forms of a number of caspases were detected; and
(ii) caspase inhibitors were not able to suppress cell death
triggered by IFN-γ. Even though the caspase cascade was
not activated, well-known hallmarks of apoptosis were
identified. DNA fragmentation and Lamin B cleavage have
previously been shown to occur independent of caspase
activation [44,45], whereas PARP cleavage has been
regarded as a caspase-indispensable event. Cleavage of
PARP to an 89-kDa fragment was however evident, but
the observed low level activation of caspase-9 was, due to
the lack of effect when adding the specific caspase-9 inhib-
itor, not considered crucial, possibly implicating other
proteases than caspases in PARP inactivation. Finally,
experiments using the antioxidant NAC indicated that
ROS are involved in S100A4/IFN-γ-mediated triggering of
apoptosis. In light of recent reports demonstrating that
both S100B and S100A8/S100A9 induced apoptosis in an
oxidant-dependent manner this result is highly interesting
[33,46].
Conclusions
In conclusion, we have demonstrated that extracellular
S100A4 induces NF-κB transactivation and possesses
proapoptotic activity through sensitization of IFN-γ-
induced apoptosis, but whether activation of NF-κB is
required for the observed sensitization of cell death is still
unknown. Even though the precise physiological role of
the apoptosis sensitizing effect of S100A4 awaits further
studies, it highlights yet another area of research in the
attempts to elucidate the complex biological roles of
S100A4.
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